China Pharma Holdings, Inc. (AMEX: CPHI) Stock Competitors & Peer Comparison

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TAK has a market cap of 57.4B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TAK trades at $18.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TAK's P/E ratio is 12.97. In terms of profitability, CPHI's ROE is -0.17%, compared to TAK's ROE of +0.02%. Regarding short-term risk, CPHI is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TAK's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while HLN trades at $10.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas HLN's P/E ratio is 18.85. In terms of profitability, CPHI's ROE is -0.17%, compared to HLN's ROE of +0.17%. Regarding short-term risk, CPHI is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check HLN's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TEVA has a market cap of 42.4B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TEVA trades at $36.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TEVA's P/E ratio is 12.43. In terms of profitability, CPHI's ROE is -0.17%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, CPHI is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TEVA's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ZTS trades at $77.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ZTS's P/E ratio is 11.75. In terms of profitability, CPHI's ROE is -0.17%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, CPHI is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ZTS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while VTRS trades at $16.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas VTRS's P/E ratio is 6.48. In terms of profitability, CPHI's ROE is -0.17%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, CPHI is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check VTRS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CPHI's ROE is -0.17%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, CPHI is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ITCI's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ELAN has a market cap of 12B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ELAN trades at $24.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ELAN's P/E ratio is 22.76. In terms of profitability, CPHI's ROE is -0.17%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, CPHI is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ELAN's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CPHI's ROE is -0.17%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, CPHI is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CTLT's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while RDY trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas RDY's P/E ratio is 19.97. In terms of profitability, CPHI's ROE is -0.17%, compared to RDY's ROE of +0.09%. Regarding short-term risk, CPHI is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check RDY's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ALKS trades at $47.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ALKS's P/E ratio is 49.91. In terms of profitability, CPHI's ROE is -0.17%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, CPHI is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ALKS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while LNTH trades at $100.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas LNTH's P/E ratio is 16.94. In terms of profitability, CPHI's ROE is -0.17%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, CPHI is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check LNTH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while AMRX trades at $17.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas AMRX's P/E ratio is 19.49. In terms of profitability, CPHI's ROE is -0.17%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, CPHI is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AMRX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while INDV trades at $34.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas INDV's P/E ratio is 9.55. In terms of profitability, CPHI's ROE is -0.17%, compared to INDV's ROE of -2.16%. Regarding short-term risk, CPHI is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check INDV's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ALVOW trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, CPHI's ROE is -0.17%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, CPHI is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ALVOW's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while RGC trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas RGC's P/E ratio is -387.32. In terms of profitability, CPHI's ROE is -0.17%, compared to RGC's ROE of -2.32%. Regarding short-term risk, CPHI is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check RGC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while SUPN trades at $43.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas SUPN's P/E ratio is 14.29. In terms of profitability, CPHI's ROE is -0.17%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, CPHI is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SUPN's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while BHC trades at $6.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas BHC's P/E ratio is 1.61. In terms of profitability, CPHI's ROE is -0.17%, compared to BHC's ROE of +0.89%. Regarding short-term risk, CPHI is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check BHC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CPHI's ROE is -0.17%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CPHI is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DCPH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while HCM trades at $12.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas HCM's P/E ratio is 4.64. In terms of profitability, CPHI's ROE is -0.17%, compared to HCM's ROE of +0.01%. Regarding short-term risk, CPHI is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check HCM's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, CPHI's ROE is -0.17%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, CPHI is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AVDL's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TRLV trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TRLV's P/E ratio is -4.80. In terms of profitability, CPHI's ROE is -0.17%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, CPHI is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check TRLV's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while PRGO trades at $14.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas PRGO's P/E ratio is 5.80. In terms of profitability, CPHI's ROE is -0.17%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, CPHI is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check PRGO's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CPHI's ROE is -0.17%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, CPHI is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check EMBCV's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas DVAX's P/E ratio is -41.89. In terms of profitability, CPHI's ROE is -0.17%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, CPHI is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DVAX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ALVO trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ALVO's P/E ratio is -14.56. In terms of profitability, CPHI's ROE is -0.17%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, CPHI is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ALVO's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ANIP trades at $72.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ANIP's P/E ratio is 8.86. In terms of profitability, CPHI's ROE is -0.17%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, CPHI is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ANIP's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ETON trades at $59.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ETON's P/E ratio is 129.96. In terms of profitability, CPHI's ROE is -0.17%, compared to ETON's ROE of +0.40%. Regarding short-term risk, CPHI is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ETON's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TARO's P/E ratio is 30.05. In terms of profitability, CPHI's ROE is -0.17%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CPHI is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TARO's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while PAHC trades at $37.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas PAHC's P/E ratio is 12.86. In terms of profitability, CPHI's ROE is -0.17%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, CPHI is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check PAHC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while HROW trades at $37.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas HROW's P/E ratio is -37.65. In terms of profitability, CPHI's ROE is -0.17%, compared to HROW's ROE of -1.04%. Regarding short-term risk, CPHI is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check HROW's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while CRON trades at $3.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas CRON's P/E ratio is 32.10. In terms of profitability, CPHI's ROE is -0.17%, compared to CRON's ROE of +0.06%. Regarding short-term risk, CPHI is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CRON's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while PCRX trades at $25.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas PCRX's P/E ratio is 9.91. In terms of profitability, CPHI's ROE is -0.17%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, CPHI is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PCRX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, AMPH has a market cap of 970.5M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while AMPH trades at $22.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas AMPH's P/E ratio is 7.51. In terms of profitability, CPHI's ROE is -0.17%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, CPHI is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AMPH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CPHI's ROE is -0.17%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, CPHI is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PETQ's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, COLL has a market cap of 822.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while COLL trades at $25.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas COLL's P/E ratio is 3.18. In terms of profitability, CPHI's ROE is -0.17%, compared to COLL's ROE of +0.16%. Regarding short-term risk, CPHI is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check COLL's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, GLAS has a market cap of 768.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while GLAS trades at $9.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas GLAS's P/E ratio is -17.73. In terms of profitability, CPHI's ROE is -0.17%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, CPHI is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check GLAS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, IRWD has a market cap of 698M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while IRWD trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas IRWD's P/E ratio is 5.44. In terms of profitability, CPHI's ROE is -0.17%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, CPHI is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check IRWD's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, EVO has a market cap of 678.5M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while EVO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas EVO's P/E ratio is -2.70. In terms of profitability, CPHI's ROE is -0.17%, compared to EVO's ROE of -0.27%. Regarding short-term risk, CPHI is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check EVO's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, AQST has a market cap of 629.8M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while AQST trades at $5.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas AQST's P/E ratio is -7.72. In terms of profitability, CPHI's ROE is -0.17%, compared to AQST's ROE of +2.44%. Regarding short-term risk, CPHI is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check AQST's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, EOLS has a market cap of 584.8M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while EOLS trades at $8.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas EOLS's P/E ratio is -28.12. In terms of profitability, CPHI's ROE is -0.17%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, CPHI is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check EOLS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CPHI's ROE is -0.17%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CPHI is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check BDSI's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TLRY has a market cap of 513.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TLRY trades at $4.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TLRY's P/E ratio is -4.23. In terms of profitability, CPHI's ROE is -0.17%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, CPHI is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TLRY's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, KMDA has a market cap of 476.6M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while KMDA trades at $8.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas KMDA's P/E ratio is 21.74. In terms of profitability, CPHI's ROE is -0.17%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, CPHI is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check KMDA's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, CGC has a market cap of 421.9M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while CGC trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas CGC's P/E ratio is -0.60. In terms of profitability, CPHI's ROE is -0.17%, compared to CGC's ROE of -0.33%. Regarding short-term risk, CPHI is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CGC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TKNO has a market cap of 381.7M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TKNO trades at $7.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TKNO's P/E ratio is -22.97. In terms of profitability, CPHI's ROE is -0.17%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, CPHI is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check TKNO's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, EBS has a market cap of 305.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while EBS trades at $5.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas EBS's P/E ratio is 4.11. In terms of profitability, CPHI's ROE is -0.17%, compared to EBS's ROE of -0.36%. Regarding short-term risk, CPHI is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check EBS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CPHI's ROE is -0.17%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, CPHI is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ALIM's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CPHI's ROE is -0.17%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, CPHI is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check LNDC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ACB has a market cap of 248.4M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ACB trades at $4.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ACB's P/E ratio is -8.19. In terms of profitability, CPHI's ROE is -0.17%, compared to ACB's ROE of -0.21%. Regarding short-term risk, CPHI is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ACB's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CPHI's ROE is -0.17%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, CPHI is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check TYHT's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ORGO has a market cap of 223.9M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ORGO trades at $1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ORGO's P/E ratio is 58.00. In terms of profitability, CPHI's ROE is -0.17%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, CPHI is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ORGO's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, CRDL has a market cap of 223.6M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while CRDL trades at $1.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas CRDL's P/E ratio is -7.73. In terms of profitability, CPHI's ROE is -0.17%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, CPHI is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check CRDL's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, SIGA has a market cap of 219.5M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while SIGA trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas SIGA's P/E ratio is 11.33. In terms of profitability, CPHI's ROE is -0.17%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, CPHI is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SIGA's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, DERM has a market cap of 205.6M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while DERM trades at $7.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas DERM's P/E ratio is -20.19. In terms of profitability, CPHI's ROE is -0.17%, compared to DERM's ROE of -0.20%. Regarding short-term risk, CPHI is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DERM's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas REPH's P/E ratio is -8.04. In terms of profitability, CPHI's ROE is -0.17%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CPHI is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check REPH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, OGI has a market cap of 171M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while OGI trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas OGI's P/E ratio is 2.73. In terms of profitability, CPHI's ROE is -0.17%, compared to OGI's ROE of +0.21%. Regarding short-term risk, CPHI is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check OGI's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, LFCR has a market cap of 170.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while LFCR trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas LFCR's P/E ratio is -4.24. In terms of profitability, CPHI's ROE is -0.17%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, CPHI is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check LFCR's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas THTX's P/E ratio is -28.83. In terms of profitability, CPHI's ROE is -0.17%, compared to THTX's ROE of +0.17%. Regarding short-term risk, CPHI is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check THTX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ASRT's P/E ratio is -7.10. In terms of profitability, CPHI's ROE is -0.17%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, CPHI is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ASRT's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, CPIX has a market cap of 126.8M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while CPIX trades at $8.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas CPIX's P/E ratio is -21.15. In terms of profitability, CPHI's ROE is -0.17%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, CPHI is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check CPIX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, BGM has a market cap of 122.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while BGM trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas BGM's P/E ratio is -1.11. In terms of profitability, CPHI's ROE is -0.17%, compared to BGM's ROE of -0.07%. Regarding short-term risk, CPHI is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check BGM's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CPHI's ROE is -0.17%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CPHI is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SCTL's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas PROC's P/E ratio is 1.53. In terms of profitability, CPHI's ROE is -0.17%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CPHI is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PROC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CPHI's ROE is -0.17%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, CPHI is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check OPTN's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CPHI's ROE is -0.17%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, CPHI is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ZOM's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CPHI's ROE is -0.17%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, CPHI is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check GRVI's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ZYBT has a market cap of 82M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ZYBT trades at $1.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ZYBT's P/E ratio is -7.86. In terms of profitability, CPHI's ROE is -0.17%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, CPHI is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ZYBT's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CPHI's ROE is -0.17%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CPHI is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ZYNE's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, INCR has a market cap of 68.5M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while INCR trades at $5.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas INCR's P/E ratio is -13.34. In terms of profitability, CPHI's ROE is -0.17%, compared to INCR's ROE of -0.09%. Regarding short-term risk, CPHI is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check INCR's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CPHI's ROE is -0.17%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, CPHI is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SSIC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TLPH trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TLPH's P/E ratio is -3.87. In terms of profitability, CPHI's ROE is -0.17%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, CPHI is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TLPH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CPHI's ROE is -0.17%, compared to VLNS's ROE of N/A. Regarding short-term risk, CPHI is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check VLNS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas DRRX's P/E ratio is -4.44. In terms of profitability, CPHI's ROE is -0.17%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, CPHI is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DRRX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CPHI's ROE is -0.17%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, CPHI is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check JUPW's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas QLI's P/E ratio is -4.92. In terms of profitability, CPHI's ROE is -0.17%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CPHI is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check QLI's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while RMTI trades at $8.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas RMTI's P/E ratio is -6.10. In terms of profitability, CPHI's ROE is -0.17%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, CPHI is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check RMTI's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CPHI's ROE is -0.17%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CPHI is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check HEXO's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, TXMD has a market cap of 25.7M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while TXMD trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas TXMD's P/E ratio is 113.09. In terms of profitability, CPHI's ROE is -0.17%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, CPHI is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TXMD's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while AYTU trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas AYTU's P/E ratio is -1.17. In terms of profitability, CPHI's ROE is -0.17%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, CPHI is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AYTU's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas CYTH's P/E ratio is -0.80. In terms of profitability, CPHI's ROE is -0.17%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, CPHI is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CYTH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas EVOK's P/E ratio is -7.97. In terms of profitability, CPHI's ROE is -0.17%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, CPHI is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check EVOK's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, OPTH has a market cap of 15.9M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while OPTH trades at $4.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas OPTH's P/E ratio is -18.08. In terms of profitability, CPHI's ROE is -0.17%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, CPHI is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check OPTH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CPHI's ROE is -0.17%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, CPHI is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ACRX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, CABR has a market cap of 12.6M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while CABR trades at $1.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas CABR's P/E ratio is -2.48. In terms of profitability, CPHI's ROE is -0.17%, compared to CABR's ROE of -3.28%. Regarding short-term risk, CPHI is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check CABR's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CPHI's ROE is -0.17%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, CPHI is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check AGRX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CPHI's ROE is -0.17%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, CPHI is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check NLTX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas LCI's P/E ratio is -0.04. In terms of profitability, CPHI's ROE is -0.17%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CPHI is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check LCI's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ADMP's P/E ratio is -0.08. In terms of profitability, CPHI's ROE is -0.17%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, CPHI is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ADMP's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while YCBD trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas YCBD's P/E ratio is -1.25. In terms of profitability, CPHI's ROE is -0.17%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, CPHI is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check YCBD's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, GELS has a market cap of 5.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while GELS trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas GELS's P/E ratio is -1.11. In terms of profitability, CPHI's ROE is -0.17%, compared to GELS's ROE of -0.25%. Regarding short-term risk, CPHI is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check GELS's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas MNK's P/E ratio is -0.44. In terms of profitability, CPHI's ROE is -0.17%, compared to MNK's ROE of -0.36%. Regarding short-term risk, CPHI is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check MNK's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas FLGC's P/E ratio is -0.19. In terms of profitability, CPHI's ROE is -0.17%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, CPHI is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check FLGC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while UPC trades at $4.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas UPC's P/E ratio is -0.62. In terms of profitability, CPHI's ROE is -0.17%, compared to UPC's ROE of -0.03%. Regarding short-term risk, CPHI is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check UPC's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while SBFM trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas SBFM's P/E ratio is -0.19. In terms of profitability, CPHI's ROE is -0.17%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, CPHI is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check SBFM's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas PLXP's P/E ratio is -0.22. In terms of profitability, CPHI's ROE is -0.17%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, CPHI is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check PLXP's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas ATNX's P/E ratio is -0.02. In terms of profitability, CPHI's ROE is -0.17%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, CPHI is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ATNX's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while SNOA trades at $1.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas SNOA's P/E ratio is -1.11. In terms of profitability, CPHI's ROE is -0.17%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, CPHI is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check SNOA's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while SHPH trades at $3.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas SHPH's P/E ratio is -0.17. In terms of profitability, CPHI's ROE is -0.17%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, CPHI is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check SHPH's competition here

China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPHI stands at 36.6M. In comparison, RDHL has a market cap of 2.1M. Regarding current trading prices, CPHI is priced at $0.90 on the AMEX, while RDHL trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPHI currently has a P/E ratio of -2.10, whereas RDHL's P/E ratio is 0.13. In terms of profitability, CPHI's ROE is -0.17%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, CPHI is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check RDHL's competition here